Why is Aurobindo Pharma falling/rising?

As of 17-Jul, Aurobindo Pharma Ltd. is currently priced at 1,153.50, reflecting a slight increase of 0.6 (0.05%). The stock has shown a performance of +2.13% over the past week and +3.83% over the past month, which contrasts with the Sensex's decline of -1.12% and a modest gain of +0.83% respectively. However, the stock has underperformed its sector by -0.37% today, and there has been a notable decrease in investor participation, with delivery volume falling by -23.46% against the 5-day average. Despite a low Debt to Equity ratio and a reasonable Price to Book Value, the stock's year-to-date return is down -13.61%, and its one-year return is -15.96%, indicating challenges despite a 5.3% rise in profits.
In the broader market context, Aurobindo Pharma's recent short-term performance has outpaced the Sensex, which is noteworthy given the overall market conditions. The stock's high institutional holdings at 41.31% suggest that knowledgeable investors are backing the company, potentially providing stability. However, the stock's performance over the longer term remains concerning, with a three-year return of +110.22% compared to the Sensex's +53.01%, indicating that while it has historically performed well, recent trends show a decline that may be affecting investor sentiment.